



Alkeran[®] (melphalan) – First-time generic

- On June 26, 2017, Alvogen launched an [AB-rated](#) generic version of ApoPharma's [Alkeran \(melphalan\)](#) 2 mg tablets.
- Alkeran is indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
- Melphalan is also generically available as a [50 mg vial](#) for intravenous infusion, and as a branded propylene glycol-free formulation ([Evomela[®]](#)).
 - Intravenous melphalan and Evomela are indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
 - Evomela is also indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
- Alkeran carries a boxed warning stating that it should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.
 - Severe bone marrow suppression with resulting infection or bleeding may occur.
 - Alkeran is leukemogenic in humans.
 - Alkeran produces chromosomal aberrations *in vitro* and *in vivo* and, therefore, should be considered potentially mutagenic in humans.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.